-
Alzamend Neuro NASDAQ:ALZN Alzamend Neuro is a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer’s disease. With its product candidates, the company aims to bring treatments or cures to market at a reasonable cost as quickly as possible. Its current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of its product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.
Location: 3802 Spectrum Blvd,, Suite C112c, Florida, 33612, United States | Website: alzamend.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
3.669M
Cash
1.194M
Avg Qtr Burn
-1.507M
Short % of Float
3.82%
Insider Ownership
4.55%
Institutional Own.
0.94%
Qtr Updated
07/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AL001 Details Alzheimer's disease | Phase 2 Initiation | |
AL001 Details Major depressive disorder | Phase 2 Initiation | |
AL001 Details Post-traumatic stress disorder | Phase 2 Initiation | |
AL001 Details Bipolar disease | Phase 2 Initiation | |
ALZN002 Details Alzheimer's disease, Dementia | Phase 1/2 Data readout |